This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Landman-Parker, J. Articles by Oberlin, O. Search for Related Content PubMed PubMed Citation Articles by Landman-Parker, J. Articles by Oberlin, O. Social Bookmarking                            What's this?

Localized Childhood Hodgkin’s Disease: Response-Adapted Chemotherapy With Etoposide, Bleomycin, Vinblastine, and Prednisone Before Low-Dose Radiation Therapy—Results of the French Society of Pediatric Oncology Study MDH90

From the Departments of Pediatric Hematology and Oncology, Hopital d’Enfants Armand Trousseau, Institut Curie, Hopital Saint Louis, Paris; Institut Gustave Roussy, Villejuif; Hopital Debrousse, Lyon; Hopital Pellegrin, Bordeaux; Hopital Purpan, Toulouse; and Hopital La Timone, Marseille, France.

Address reprint requests to Judith Landman-Parker, MD, Service d’Hématologie et d’Oncologie Pédiatrique, Hôpital d’Enfants Armand Trousseau, 26 avenue Arnold Netter, 75012 Paris, France; email judith.landman-parker{at}trs.ap-hop-paris.fr

PURPOSE: The French Society of Pediatric Oncology MDH82 study demonstrated the effectiveness of 20 Gy irradiation of involved fields after doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) or mechlorethamine, vincristine, procarbazine, and prednisone/ABVD chemotherapy in children with localized Hodgkin’s disease (HD). The response to primary chemotherapy was the only predictor of survival. To reduce long-term treatment complications without compromising efficacy, the MDH90 study was based on a new chemotherapy regimen devoid of both alkylating agents and anthracycline, followed by 20 Gy of radiotherapy (RT) for good responders.

PATIENTS AND METHODS: From January 1990 to July 1996, 202 children were enrolled from 30 institutions. Good responders to four cycles of vinblastine, bleomycin, etoposide (VP16), and prednisone (VBVP) were given 20 Gy of RT and no further therapy. Poor responders were given vincristine, procarbazine, prednisone, and doxorubicin. After a second evaluation, good responders were given 20 Gy of RT, and poor responders were given 40 Gy of RT.

RESULTS: One hundred seventy-one patients (85%) were good responders to VBVP, 27 (15%) were poor responders, and four did not respond. With a median follow-up of 74 months (range, 25 to 117 months), the 5-year overall survival rate (mean ± SD) is 97.5% ± 2.1%, and the event-free survival rate (mean ± SD) is 91.1% ± 1.8%. Significant predictors of worse event-free survival in multivariate analysis were hemoglobin < 10.5 g/L, "b" biologic class, and nodular sclerosis.

CONCLUSION: These results suggest that most children with clinical stage I and II HD can be treated with chemotherapy devoid of alkylating agents and anthracycline, followed by low-dose RT.

Preliminary results of this study were presented at the Annual Meeting of American Society of Hematology (ASH), 1996.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Claviez, C. Canals, D. Dierickx, J. Stein, I. Badell, A. Pession, S. Mackinnon, S. Slavin, J.-H. Dalle, M. J. Chacon, et al. Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation Blood, September 3, 2009; 114(10): 2060 - 2067. [Abstract] [Full Text] [PDF]

				C. L. Schwartz, L. S. Constine, D. Villaluna, W. B. London, R. E. Hutchison, R. Sposto, S. E. Lipshultz, C. S. Turner, P. A. deAlarcon, and A. Chauvenet A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425 Blood, September 3, 2009; 114(10): 2051 - 2059. [Abstract] [Full Text] [PDF]

				C. K. Tebbi, W. B. London, D. Friedman, D. Villaluna, P. A. De Alarcon, L. S. Constine, N. P. Mendenhall, R. Sposto, A. Chauvenet, and C. L. Schwartz Dexrazoxane-Associated Risk for Acute Myeloid Leukemia/Myelodysplastic Syndrome and Other Secondary Malignancies in Pediatric Hodgkin's Disease J. Clin. Oncol., February 10, 2007; 25(5): 493 - 500. [Abstract] [Full Text] [PDF]

				S. S. Donaldson, M. P. Link, H. J. Weinstein, S. N. Rai, S. Brain, A. L. Billett, C. A. Hurwitz, M. Krasin, L. E. Kun, K. C. Marcus, et al. Final Results of a Prospective Clinical Trial With VAMP and Low-Dose Involved-Field Radiation for Children With Low-Risk Hodgkin's Disease J. Clin. Oncol., January 20, 2007; 25(3): 332 - 337. [Abstract] [Full Text] [PDF]

				L. M.L. Chow, P. C. Nathan, D. C. Hodgson, D. Jenkin, S. Weitzman, R. M. Grant, D. Manson, A. Bross, J. J. Doyle, C. Danjoux, et al. Survival and Late Effects in Children With Hodgkin's Lymphoma Treated With MOPP/ABV and Low-Dose, Extended-Field Irradiation J. Clin. Oncol., December 20, 2006; 24(36): 5735 - 5741. [Abstract] [Full Text] [PDF]

				M. M. Hudson, M. Krasin, M. P. Link, S. S. Donaldson, C. Billups, T. E. Merchant, L. Kun, A. L. Billet, S. Kaste, N. J. Tarbell, et al. Risk-Adapted, Combined-Modality Therapy With VAMP/COP and Response-Based, Involved-Field Radiation for Unfavorable Pediatric Hodgkin's Disease J. Clin. Oncol., November 15, 2004; 22(22): 4541 - 4550. [Abstract] [Full Text] [PDF]

				C. A. Hudis, S. Van Belle, J. Chang, and K. Muenstedt rHuEPO and Treatment Outcomes: the Clinical Experience Oncologist, November 1, 2004; 9(suppl_5): 55 - 69. [Abstract] [Full Text] [PDF]

				B. Pellegrino, M.J. Terrier-Lacombe, O. Oberlin, T. Leblanc, Y. Perel, Y. Bertrand, C. Beard, C. Edan, C. Schmitt, D. Plantaz, et al. Lymphocyte-Predominant Hodgkin's Lymphoma in Children: Therapeutic Abstention After Initial Lymph Node Resection--A Study of the French Society of Pediatric Oncology J. Clin. Oncol., August 1, 2003; 21(15): 2948 - 2952. [Abstract] [Full Text] [PDF]

				M. Federico, M. Bellei, P. Brice, M. Brugiatelli, A. Nagler, C. Gisselbrecht, L. Moretti, P. Colombat, S. Luminari, F. Fabbiano, et al. High-Dose Therapy and Autologous Stem-Cell Transplantation Versus Conventional Therapy for Patients With Advanced Hodgkin's Lymphoma Responding to Front-Line Therapy J. Clin. Oncol., June 15, 2003; 21(12): 2320 - 2325. [Abstract] [Full Text] [PDF]

				R. S. Smith, Q. Chen, M. M. Hudson, M. P. Link, L. Kun, H. Weinstein, A. Billett, K. J. Marcus, N. J. Tarbell, and S. S. Donaldson Prognostic Factors for Children With Hodgkin's Disease Treated With Combined-Modality Therapy J. Clin. Oncol., May 15, 2003; 21(10): 2026 - 2033. [Abstract] [Full Text] [PDF]

				O. Oberlin When Quality of Life Is the Major Challenge J. Clin. Oncol., July 15, 2002; 20(14): 3051 - 3053. [Full Text] [PDF]

				S. S. Donaldson, M. M. Hudson, K. R. Lamborn, M. P. Link, L. Kun, A. L. Billett, K. C. Marcus, C. A. Hurwitz, J. A. Young, N. J. Tarbell, et al. VAMP and Low-Dose, Involved-Field Radiation for Children and Adolescents With Favorable, Early-Stage Hodgkin's Disease: Results of a Prospective Clinical Trial J. Clin. Oncol., July 15, 2002; 20(14): 3081 - 3087. [Abstract] [Full Text] [PDF]

				A. M. Friedmann, M. M. Hudson, H. J. Weinstein, S. S. Donaldson, L. Kun, N. J. Tarbell, and M. P. Link Treatment of Unfavorable Childhood Hodgkin's Disease With VEPA and Low-Dose, Involved-Field Radiation J. Clin. Oncol., July 15, 2002; 20(14): 3088 - 3094. [Abstract] [Full Text] [PDF]

				L. R. Prosnitz Reducing Treatment-Related Morbidity and Mortality in Early-Stage Hodgkin's Disease and Why the Recent Southwest Oncology Group Trial Is Not the Way to Go J. Clin. Oncol., May 1, 2002; 20(9): 2225 - 2228. [Full Text] [PDF]